EHA 2018 | The future of leukemia treatment leans towards immunotherapy
Chemotherapy is becoming increasingly less desirable as a form of treatment, due to its systemic and burdensome nature. Instead, immunotherapy has been dominating the field of treatment, with agents that are often much more tolerable and, in some cases, more effective. Here, Robin Foà, MD, of Sapeinza Univesity of Rome, Rome, Italy, speaks to us about the use of tyrosine kinase inhibitors, which have revolutionized treatment for chronic myeloid leukemia (CML) and how this treatment is slowly being adapted for other hematological cancers, such as acute lymphoblastic leukemia (ALL). Prof. Foa, speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, concludes by mentioning why immunotherapy drugs are becoming increasingly more popular, particularly for certain age groups.
